Q3 2025 Gerresheimer AG Earnings Call Transcript
Key Points
- Gerresheimer AG (GRRMF) reported a positive free cash flow of €21 million in the third quarter, indicating improved cash management.
- The company expects a stronger fourth quarter due to the ramp-up of new production lines for drug delivery systems.
- The acquisition of Bormioli Pharma has strengthened Gerresheimer AG's market position and contributed to revenue and EBITDA growth.
- The FDA granted approval for Gerresheimer AG's innovative on-body drug delivery device, GX Impulse, showcasing the company's expertise in advanced technology.
- Gerresheimer AG received an A rating from CDP for climate-related goals and processes, highlighting its commitment to sustainability.
- Gerresheimer AG (GRRMF) issued a profit warning for the 2025 financial year, with organic revenues and adjusted EBITDA below expectations.
- The company's adjusted EBITDA margin decreased by 1.7 percentage points compared to the previous year, indicating margin pressure.
- Market recovery in the cosmetic and oral liquid markets has been slower than anticipated, impacting revenue growth.
- The company's leverage ratio stands at 4.15, raising concerns about its debt levels and financial flexibility.
- Gerresheimer AG is undergoing an audit related to bill and hold contracts, which could impact financial reporting and investor confidence.
Good morning to all of you. Welcome to our Q3 25 for 9 months.
25 results call with us today.
Good morning to all of you. Welcome to our Q3 25 or 9 months 25 results call. With us today are our CEO Demaimson, and our new CFO Walsh Lemann, who will, run you through the Q3 Q3 and 9 months results and then, go into the financials. Afterwards, we will be open the floor for questions and answers. With that, I hand over to Dietmar Simpson. Dietmar, please go ahead.
Yeah. Welcome, everybody.
Thank you for joining us, for this call.
As you all know, we held a conference call yesterday morning after issuing preliminary figures for the third quarter and the profit warning for the 2025 financial year, the night before.
Today, we want to provide you a full update after releasing the final numbers.
There are no changes to the preliminary figures, by the way, and if those who couldn't participate in yesterday's call the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
